The President's Council on Advisors on Science and Technology (PCAST), a group administered by the federal Office of Science and Technology Policy (OSTP), issued recommendations to improve the country's ability to accelerate vaccine production and delivery in the event of a pandemic flu outbreak.
Changing demands in drug development lead to new service combinations and models.
A Strengths, Weaknesses, Opportunities and Threats analysis of the biosimilars market is given.
Both biosimilar and generic drugs have an abbreviated approval process; however, the clinical trial requirements differ enormously.
Bristol-Myers Squibb's fit-for-purpose mode for clinical-trial materials for early-stage development seeks to achieve a better way in resource allocation. This article is part of a special issue on API Development, Formulation, Synthesis and Manufacturing.
In light of the impressive size and predicted growth of the market, there has been a rising interest in the development of biosimilars.
The main advantage of outsourcing highly potent API (HPAPI) manufacture is that it eliminates the need to invest in expensive containment infrastructure, which can also be complex to engineer, install and maintain.
Many hurdles lie between a biosimilar and success on the market. In particular, there are three main questions that companies will be asking themselves.
Both biosimilar and generic drugs have an abbreviated approval process; however, the clinical trial requirements differ enormously.
One particularly crucial parameter for nasal sprays is the size of the droplets produced during actuation, which can potentially impact bioavailability.
Last year, the global market for biological products exceeded $125 billion, accounting for 17% of the total market for pharma/biopharma products.
Week of Aug. 23, 2010: Company and People Notes: Quark and Novartis Form Agreement; Hospira CEO Retires; And More.
US Department of Health and Human Services (HHS) Secretary Kathleen Sebelius released last week an examination of the federal government's system to produce medical countermeasures, or medications, vaccines, equipment, and supplies needed for a health emergency.
Two new reports describe the vaccine market's recent growth and predict future market expansions.
Recent figures published by the EMA relating to centralized procedure activities for human medicines appear to show a marked slow down in the number of generic product applications started and finalised this year to date.
Recent figures published by the EMA relating to centralized procedure activities for human medicines appear to show a marked slow down in the number of generic product applications started and finalized this year to date (9 and 12, respectively).
Eli Lilly Ends Semagacestat Program; Selecta Appoints CEO; And More.
Making highly potent active pharmaceutical ingredients (HPAPIs) can be costly because the process often requires equipment specialized to achieve containment and extra attention to safety concerns. Pharmaceutical professionals may wonder whether disposable components, which have reduced the cost of some operations, might be appropriate in the manufacture of HPAPIs.
Penwest and Endo to Merge; Watson Makes Senior Appointments; And More.
In a draft guidance published this week, the US Food and Drug Administration recommended that makers of transdermal and transmucosal drug-delivery systems use "an appropriate scientific approach" during product design, development, and manufacturing to minimize the amount of residual drug substance present at the end of the products' labeled use periods.
FDA Approves Flu Vaccines; Caraco Names COO; And More.
Industry's focus on cost cutting has led to a dangerous gap in training and knowledge.
Industry can meet its responsibility to society by considering innovative pricing and partnerships.
Pharmaceutical Technology talked to experts in siRNA-drug development to gain insight into the characteristics, processes, and challenges of this class of therapeutics.
As emerging markets become increasingly important for the pharmaceutical majors, companies are re-evaluating their outsourcing strategies. This article is part of the 2010 Outsourcing Resources special issue.
